Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics

Psychiatric Services

Volumn 61, Issue 12, 2010, Pages 1239-1247

  Lang, Kathleen ^a   Meyers, Juliana L ^a   Korn, Jonathan R ^a   Lee, Seina ^b   Sikirica, Mirko ^c   Crivera, Concetta ^c   Dirani, Riad ^c   Menzin, Joseph ^a  

^a Boston Health Economics Inc   (United States)

^b JOHNSON AND JOHNSON   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; BILLING AND CLAIMS; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM GAP IN TREATMENT; MEDICAID; MEDICARE; MEDICATION CONSISTENCY; MEDICATION PERSISTENCE; MEDICATION POSSESSION RATIO; MENTAL HOSPITAL; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; PSYCHOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SUBSTANCE ABUSE; UNITED STATES;

EID: 79953092448     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.2010.61.12.1239     Document Type: Article

References (25)

1. Schizophrenia. NIH pub no 06-3517. Bethesda, Md, US Department of Health and Human Services. National Institutes of Health, 2006
2. Long-acting injectable antipsychotics: a useful and well tolerated option in elderly patients with psychotic illnesses. Drugs and Therapy Perspectives 20:7-10, 2004
3. Perkins D: Predictors of noncompliance in patients with schizophrenia. Journal of Clinical Psychiatry 63:1121-1128, 2006
4. Liu-Seifert H, Adams DH, Kinon BJ: Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Medicine 3:21, 2005
5. Gilmer TP, Dolder CR, Larco J, et al: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry 161:692-699, 2004 (Pubitemid 38445514)
6. Ereshefsky L, Mannaert E: Pharmacokinetic profile and clinical efficacy of longacting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs in R&D 6: 129-137, 2005 (Pubitemid 40994250)
7. Svarstad BL, Shireman TI, Sweeney JK: Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatric Services 52:805-811, 2001 (Pubitemid 32577440)
8. Valenstein M, Copeland LA, Blow FC, et al: Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care 40:630-639, 2002
9. Gianfrancesco F, Rajagopalan KS, Sajatovic M, et al: Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Psychiatry Research 144:177-189, 2006 (Pubitemid 44666176)
10. Becker MA, Young MS, Ochshom E, et al: The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia. Administration and Policy in Mental Health 34:307-314, 2007 (Pubitemid 46742594)
11. Valenstein M, Blow FC, Copeland LA, et al: Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophrenia Bulletin 30:255-264, 2004 (Pubitemid 38828533)
12. Keith SJ, Pani L, Nick B, et al: Practical application of pharmacotherapy with longacting risperidone for patients with schizophrenia. Psychiatric Services 55:997-1005, 2004 (Pubitemid 39209681)
13. Weiden PJ, Kozma C, Grogg A, et al: Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric Services 55:886-891, 2004 (Pubitemid 39025215)
14. Love RC: Strategies for increasing treatment compliance: the role of long-acting antipsychotics. American Journal of Health-System Pharmacy 59(22 suppl 8):S10-S15, 2002
15. McEvoy JP: Risks versus benefits of different types of long-acting injectable antipsychotics. Journal of Clinical Psychiatry 67:15-18, 2006
16. Keks NA, Ingham M, Khan A, et al: Longacting injectable risperidone v olanzapine tablets for schizophrenia or schizoaffective disorder: a randomised, controlled, openlabel study. British Journal of Psychiatry 191:131-139, 2007 (Pubitemid 47204533)
17. Olfson M, Marcus SC, Ascher-Svanum H: Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophrenia Bulletin 33:1379-1387, 2007 (Pubitemid 350022772)
18. Kane JM, Eerdekens M, Lindenmayer JP, et al: Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. American Journal of Psychiatry 160:1125-1132, 2003 (Pubitemid 41070972)
19. Ascher-Svanum H, Zhu B, Faries D, et al: A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. Journal of Clinical Psychiatry 67:1114-1123, 2007
20. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Journal of Clinical Epidemiology 45:613-619, 1992
21. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 40:373-383, 1987 (Pubitemid 17055592)
22. Shi L, Ascher-Svanum H, Zhu B, et al: Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatric Services 58:482-488, 2007 (Pubitemid 46640638)
23. Martin BC, Miller LS: Expenditures for treating schizophrenia: a population-based study of Georgia Medicaid recipients. Schizophrenia Bulletin 24:479-488, 1998 (Pubitemid 28378232)
24. Coldham EL, Addington J, Addington D: Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica 106:286-290, 2002
25. Menzin J, Boulanger L, Friedman M, et al: Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatric Services 54:719-723, 2003 (Pubitemid 36752965)